-
Mipomersen (INN;
trade name
Kynamro) is a drug used to
treat homozygous familial hypercholesterolemia and is
administered by
subcutaneous injection. There...
- off-target effects, non-specific binding, and
unwanted gene
silencing Kynamro was
approved by the FDA in
January 2013 for the
treatment of homozygous...
- Isis and
Genzyme entered into a
partnered drug
candidate mipomersen (
Kynamro),
intended to
treat homozygous familial hypercholesterolemia, and other...
-
chylomicronaemia syndrome in May 2019. In
January 2013
mipomersen (marketed as
Kynamro) was
approved by the FDA for the
treatment of
homozygous familial hypercholesterolemia...
-
phosphorothioate antisense oligonucleotides fomivirsen (Vitravene) and
mipomersen (
Kynamro) for
human therapeutic use. In virology, the term "sense" has a slightly...
-
Retrieved 31
January 2013
Staff (29
January 2013) FDA
approves new
orphan drug
Kynamro to
treat inherited cholesterol disorder U.S. Food and Drug Administration...
-
drugs fomivirsen (Vitravene), Oblimersen, Alicaforsen, and
Mipomersen (
Kynamro).
Further examples of
these include:
Diazinon Fenitrothion Fenthion Thiotepa...
-
Iprivask (Desirudin), for atherothrombosis, Now
owned by
Bausch Health.
Kynamro (Mipomersen), an
antisense drug
invented by Isis
Pharmaceuticals and acquired...
- PMC 3030471. PMID 20707673. Wong E,
Goldberg T (February 2014). "Mipomersen (
kynamro): a
novel antisense oligonucleotide inhibitor for the
management of homozygous...
-
Treat Rare Disease". The New York Times. "FDA
approves new
orphan drug
Kynamro to
treat inherited cholesterol disorder" (Press release). U.S. Food and...
